Back to top

Analyst Blog

Zacks Equity Research

Sanofi's Menactra Data Published

SNY GSK

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Sanofi’s (SNY - Analyst Report) vaccines division, Sanofi Pasteur, recently announced that the data from the pivotal trial of Menactra (meningococcal groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) has been published by the Pediatric Infectious Disease Journal (PIDJ).

In the trial, Menactra demonstrated a promising efficacy profile as two-dose vaccine for infants and toddlers aged between 9 months and 23 months. It was observed that the use of Menactra provided protection against four clinically meningococcal strains.

We note that the Food and Drug Administration used data from the above mentioned pivotal trial to approve Menactra in April 2011. Menactra was first approved in 2005 as meningococcal conjugate vaccine for people aged between 11 years and 55 years. In subsequent years, the product’s label was expanded to include infants above 9 months.   

In the third quarter of 2012, Menactra generated sales of €208 million accounting for approximately 14% of total vaccines sales at Sanofi. In the US, Menactra sales inched up 0.6% to €195 million.

Meningococcal disease, which includes meningitis, is estimated to affect about 800 to 1,200 people in the US annually. About 10% of the affected people could die and survivors could be afflicted by permanent disabilities like hearing loss, neurological damage and limb amputations. Currently, approved vaccines for meningococcal diseases include GlaxoSmithKline’s (GSK - Analyst Report) MenHibrix (meningococcal groups C and Y and haemophilus b tetanus toxoid conjugate vaccine).

We are pleased with the company’s efforts to develop its pipeline. We expect Sanofi to continue to contain operating costs in order to increase earnings in the face of weakening sales of some of its biggest products. We also expect the company to pursue bolt-on acquisitions.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%